Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Blueberry Therapeutics

Blueberry Therapeutics
2011 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$13M LATEST DEAL AMOUNT
4 INVESTORS
Description

Developer of innovative nanomedicines designed to offer treatment of bacterial infection and inflammation. The company's products are produced through a nanopolymer drug delivery platform which formulates candidate drugs to enhance delivery into cells and tissue, as well as develop therapies to tackle the healthcare needs for antibiotic resistance, enabling patients to combat bacterial infection by neutralizing resistance in combination with standard antibiotics.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • Mereside, Alderley Park
  • Cheshire
  • Alderley Edge SK10 4TG
  • England, United Kingdom

+44 01625 000000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Blueberry Therapeutics’s full profile, request a free trial.

Blueberry Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series B) 14-Aug-2018 $13M 000.00 Completed Generating Revenue
3. Early Stage VC 13-Dec-2017 00.000 00.00 000.00 Completed Clinical Trials - Phase 2
2. Early Stage VC 05-May-2016 $4.31M $5.79M Completed Clinical Trials - Phase 2
1. Angel (individual) 08-Apr-2015 $1.49M $1.49M 00.000 Completed Clinical Trials - Phase 2
To view this company’s complete deal history including valuation and funding, request access »

Blueberry Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
A Ordinary 000,000 00.000000 00.00 00.00 00 00.00 00.00
Ordinary 000,000 00.000000 00.00 00.00 00 00.00 0.000
To view this company’s complete Cap Table, request access »

Blueberry Therapeutics Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
A&B (HK) Company Corporation Minority 000 0000 000000 0
China Medical System Corporation Minority 000 0000 000000 0
Catapult Ventures Venture Capital Minority 000 0000 000000 0
InClin Other Minority 000 0000 000000 0

Blueberry Therapeutics Executive Team (9)

Name Title Board
Seat
Contact
Info
John Ridden Ph.D Co-Founder, Chief Executive Officer & Board Member
David Cook Ph.D Chief Scientific Officer
Tony Sedgwick Advisor to the Board
Alex O'Neill Scientific Advisor
Liam Good Ph.D Scientific Advisor

1 Former Executive

You’re viewing 5 of 9 executives. Get the full list »

Blueberry Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Andrew Kay Self Chairman 000 0000
Gareth King Ph.D Catapult Ventures Board Observer 000 0000
Huaizheng Peng Ph.D Self Board Member 000 0000
John Ridden Ph.D Blueberry Therapeutics Co-Founder, Chief Executive Officer & Board Member 000 0000
Rita Dobmeyer Ph.D Blueberry Therapeutics Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 6 board members. Get the full list »